시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
방광암 치료 및 진단 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 치료별, 진단별, 암 유형별, 지역별 부문, 경쟁(2020-2030년)
Bladder Cancer Therapeutics and Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutics, By Diagnostics, By Cancer Type, By Region & Competition, 2020-2030F
상품코드 : 1691780
리서치사 : TechSci Research
발행일 : 2025년 03월
페이지 정보 : 영문 180 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,500 ￦ 6,511,000
Unprintable PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.
US $ 5,500 ￦ 7,957,000
PDF and Excel (Multi-User License) help
PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.
US $ 8,000 ￦ 11,575,000
PDF and Excel (Custom Research License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

세계 방광암 치료 및 진단 시장은 2024년 4억 5,022만 달러로 평가되었고, 예측 기간 동안 7.50%의 연평균 성장률(CAGR)을 나타낼 것으로 예상됩니다.

방광암은 방광 내벽의 건강한 세포(대부분 요로상피세포)가 통제할 수 없을 정도로 변화하고 확대되어 종양으로 알려진 종괴를 형성할 때 발생합니다. 신우, 요관, 요도는 모두 요로상피세포로 덮여 있습니다. 요로상피암의 또 다른 형태는 상부요로상피암으로 신우와 요관에 발생하는 암입니다. 이 암은 이 지침에서 방광암에 대해 설명한 것과 같은 방법으로 치료하는 경우가 많습니다. 종양은 양성과 악성으로 나뉩니다. 악성은 암 종양이 발생하여 신체의 다른 부위로 전이할 수 있는 능력을 말합니다. 양성인 경우 종양이 커질 수는 있지만 전이되지는 않습니다. 양성 방광 종양은 드물게 발생합니다. 전 세계적으로 방광암 발병률 증가, 특히 고령화가 큰 원동력이 되고 있습니다. 방광암 환자 수 증가는 더 많은 환자를 발생시키고, 진단 및 치료제에 대한 수요를 촉진하고 있습니다.

시장 개요
예측 기간 2026-2030년
시장 규모 : 2024년 4억 5,022만 달러
시장 규모 : 2030년 6억 8,928만 달러
CAGR : 2025-2030년 7.50%
급성장 부문 화학요법
최대 시장 북미

영상진단 기술의 향상, 소변 기반 바이오마커 검사, 유전자 프로파일링 등 진단 기술의 지속적인 개선으로 방광암의 조기 발견 및 진단이 향상되어 진단 약품에 대한 수요가 증가하고 있습니다. 면역요법(체크포인트 억제제 등) 및 표적치료제와 같은 새로운 치료 접근법의 개발로 치료 옵션이 확대되고 방광암 환자의 예후가 개선되고 있습니다. 이러한 기술 혁신이 시장 성장의 원동력이 되고 있습니다. 새로운 치료법, 병용요법, 개인 맞춤형 의료 접근법을 모색하기 위해 진행 중인 임상시험과 연구 이니셔티브는 시장 확대의 기회를 창출하고 있습니다. 전 세계 인구의 고령화는 방광암에 걸릴 확률을 높입니다. 노인 인구가 증가함에 따라 방광암의 유병률은 증가할 것으로 예상되며, 이는 치료 및 진단에 대한 수요 증가로 이어질 것으로 예상됩니다.

주요 시장 성장 촉진요인

혁신적인 치료법 증가

주요 시장 이슈

높은 치료비

주요 시장 동향

최소침습 수술 기술

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 방광암 치료 및 진단 시장 전망

제6장 아시아태평양의 방광암 치료 및 진단 시장 전망

제7장 유럽의 방광암 치료 및 진단 시장 전망

제8장 북미의 방광암 치료 및 진단 시장 전망

제9장 남미의 방광암 치료 및 진단 시장 전망

제10장 중동 및 아프리카의 방광암 치료 및 진단 시장 전망

제11장 시장 역학

제12장 시장 동향과 발전

제13장 세계의 방광암 치료 및 진단 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

제15장 PESTEL 분석

제16장 경쟁 구도

제17장 전략적 제안

제18장 리서치사에 대해 & 면책사항

LSH
영문 목차

영문목차

Global Bladder Cancer Therapeutics and Diagnostics Market was valued at USD 450.22 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.50% through 2030. When healthy cells in the bladder lining most frequently urothelial cells change and expand uncontrollably, forming a mass known as a tumor, bladder cancer develops. The renal pelvis, ureters, and urethra are all lined with urothelial cells. Another form of urothelial cancer, known as upper tract urothelial carcinoma, is cancer that originates in the renal pelvis and ureters. It is often treated in a manner like that discussed in this guidance for bladder cancer. A tumor may be benign or malignant. Malignant refers to the ability of a cancerous tumor to develop and metastasize to different body regions. If a tumor is benign, it can enlarge but won't spread. Rarely do benign bladder tumors occur. A rising global incidence of bladder cancer, especially in aging populations, has been a significant driver. The growing number of bladder cancer cases creates a larger patient pool, driving demand for diagnostics and therapeutics.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 450.22 Million
Market Size 2030USD 689.28 Million
CAGR 2025-20307.50%
Fastest Growing SegmentChemotherapy
Largest MarketNorth America

Continuous improvements in diagnostic techniques, including enhanced imaging technologies, urine-based biomarker tests, and genetic profiling, have improved early detection and diagnosis of bladder cancer, thereby increasing the demand for diagnostics. The development of novel therapeutic approaches, such as immunotherapies (e.g., checkpoint inhibitors) and targeted therapies, has expanded treatment options and improved outcomes for bladder cancer patients. These innovations drive market growth. Ongoing clinical trials and research initiatives to explore new treatments, combination therapies, and personalized medicine approaches create opportunities for market expansion. The aging global population is more susceptible to bladder cancer. As the elderly population grows, the prevalence of bladder cancer is expected to increase, leading to higher demand for therapeutics and diagnostics.

Key Market Drivers

Increasing Innovative Therapies

Innovative therapies in cancer therapeutics and diagnostics have transformed the way cancer is diagnosed and treated. These groundbreaking approaches offer new hope for patients and have the potential to improve outcomes while reducing side effects. For instance, according to Cancer Research UK, approximately 90% of bladder cancers in the UK are urothelial cancers, also called transitional cell cancers. Immunotherapy harnesses the body's immune system to target and destroy cancer cells. Immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines are among the most promising approaches. These therapies have shown remarkable results in various cancers, including melanoma, lung cancer, and leukemia. Precision medicine, also known as personalized medicine, tailors cancer treatment based on a patient's genetic, genomic, and molecular profile. Targeted therapies, such as tyrosine kinase inhibitors and PARP inhibitors, are designed to specifically target the genetic mutations or abnormalities driving a patient's cancer. Gene therapy involves the introduction or modification of genes to treat or prevent diseases, including cancer. CAR-T cell therapy is a prime example, where a patient's T cells are genetically engineered to target cancer cells with precision. Cancer vaccines stimulate the immune system to recognize and attack cancer cells. Therapeutic cancer vaccines aim to treat existing cancer, while preventive vaccines, like the HPV vaccine, prevent certain cancers from developing. Liquid biopsies involve analyzing blood, urine, or other bodily fluids to detect cancer-specific biomarkers, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). These tests are minimally invasive and can provide insights into a patient's cancer status, treatment response, and minimal residual disease. Innovations in radiation therapy, such as intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy, allow for highly targeted radiation delivery, minimizing damage to healthy tissue.

Key Market Challenges

High Treatment Costs

The financial burden associated with bladder cancer diagnosis and treatment affects not only patients but also healthcare systems and society. The diagnostic process for bladder cancer often includes multiple procedures, such as cystoscopy, imaging (CT scans, MRI), urine tests, and potentially invasive biopsies. These diagnostic tests and procedures can accumulate substantial costs. Bladder cancer treatment options vary depending on the stage and type of cancer. Treatments may include surgery, chemotherapy, radiation therapy, immunotherapy, or a combination of these approaches. Each of these treatment modalities carries its own cost implications. Surgical procedures for bladder cancer, whether open or minimally invasive, can be expensive. Costs include surgeon fees, operating room expenses, anesthesia, and hospitalization. Immunotherapy and targeted therapies, while offering promising outcomes, can be expensive due to the high cost of drug development and administration. Some of these treatments are administered over an extended period. External beam radiation therapy and brachytherapy are common treatments for bladder cancer. The cost of radiation therapy includes the use of specialized equipment and personnel. The cost of chemotherapy drugs, as well as the monitoring and management of side effects, can be a significant financial burden on patients and healthcare systems. Bladder cancer patients often require long-term surveillance and monitoring for recurrence. This includes regular check-ups, imaging, and urine tests, which can add to the overall cost of care.

Key Market Trends

Minimally Invasive Surgical Techniques

Minimally invasive surgical techniques, such as laparoscopic and robotic-assisted surgery, often result in smaller incisions, less pain, and faster recovery times compared to open surgery. This leads to improved post-operative outcomes and a better quality of life for bladder cancer patients. Minimally invasive procedures typically require shorter hospital stays, reducing healthcare costs and freeing up hospital resources for other patients. Robotic-assisted surgery allows for precise removal of bladder tumors while preserving healthy tissue. This is especially important for patients with non-muscle-invasive bladder cancer (NMIBC) where tumor recurrence is a concern. Smaller incisions and reduced tissue trauma lower the risk of surgical site infections, which is a significant concern in open surgeries. Patients who undergo minimally invasive procedures often experience quicker recoveries, enabling them to return to their daily activities and work sooner. Minimally invasive techniques are associated with less pain and discomfort during the post-operative period, reducing the need for heavy pain medications. Smaller incisions result in less visible scarring, which can be particularly important for patients' body image and self-esteem. Laparoscopic and robotic systems provide surgeons with enhanced visualization of the surgical site, allowing for more precise tumor removal and reduced damage to healthy tissue.

Key Market Players

Report Scope:

In this report, the Global Bladder Cancer Therapeutics and Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bladder Cancer Therapeutics and Diagnostics Market, By Therapeutics:

Bladder Cancer Therapeutics and Diagnostics Market, By Diagnostics:

Bladder Cancer Therapeutics and Diagnostics Market, By Cancer Type:

Bladder Cancer Therapeutics and Diagnostics Market, By Region:

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bladder Cancer Therapeutics and Diagnostics Market.

Available Customizations:

Global Bladder Cancer Therapeutics and Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Bladder Cancer Therapeutics and Diagnostics Market Outlook

6. Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market Outlook

7. Europe Bladder Cancer Therapeutics and Diagnostics Market Outlook

8. North America Bladder Cancer Therapeutics and Diagnostics Market Outlook

9. South America Bladder Cancer Therapeutics and Diagnostics Market Outlook

10. Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. Global Bladder Cancer Therapeutics and Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Competitive Landscape

17. Strategic Recommendations

18. About Us & Disclaimer

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기